GET DAILY SIGNALSPerspective Therapeutics (CATX) Reports Q3 2026 Loss with Pipeline Momentum Intact
Key Takeaways
- Perspective Therapeutics reported a third-quarter 2026 net loss of $32.4 million, or $0.27 per basic and diluted share, compared with a net loss of $26.0 million, or $0.35 per share, in the same period a year earlier.
- The company's reported loss per share of $0.27 came in below the consensus estimate of roughly $0.24, while grant revenue of $20,000 also fell short of analyst expectations.
- Research and development (R&D) expenses rose to $26.1 million from $20.3 million, reflecting increased investment across the company's three clinical-stage oncology programs.
- Cash, cash equivalents, and short-term investments totaled approximately $202 million as of September 30, 2026, which management expects to fund planned clinical milestones and operational investments into 2028.
- Key pipeline updates included completion of Cohort 4 enrollment in the VMT-α-NET neuroendocrine tumor program and U.S. Food and Drug Administration (FDA) Fast Track Designation for PSV359.
- For more information about this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages.
- To discover data-driven trade ideas and market signals, explore Trending AI Robots.
Why These Results Matter for a Pre-Revenue Biotech
Perspective Therapeutics is a clinical-stage radiopharmaceutical company focused on targeted alpha therapies using Lead-212 to hit cancer cells directly. With no approved products yet, its quarterly numbers revolve around clinical spending pace and pipeline updates rather than top-line revenue. This report is important because it gives investors a sense of the cash runway and progress on lead programs ahead of expected 2027 data readouts. For names like this, regulatory milestones and trial timelines often influence the stock more than the income statement.
Breaking Down the Third-Quarter Numbers
For the quarter ended September 30, 2026, CATX recorded grant revenue of $20,000, down from $209,000 a year ago. The net loss came in at $32.4 million, or $0.27 per share, versus $26.0 million, or $0.35 per share, in the prior-year quarter. The per-share loss of $0.27 was wider than the roughly $0.24 consensus estimate, and revenue also missed forecasts. Operating expenses climbed to $34.3 million from $28.1 million, led by R&D costs that increased to $26.1 million from $20.3 million. General and administrative expenses rose modestly to $8.3 million from $7.7 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
How the Market Responded
Shares moved lower after the November 9, 2026 release. In development-stage biotechs, a small miss on loss per share is often less critical than clinical updates, yet the wider loss combined with the drop in minimal grant revenue seemed to pressure sentiment. Investors are weighing higher near-term spending against the company’s runway into 2028 and several potentially meaningful data readouts slated for 2027. The reaction highlights how sensitive these names remain to signals on capital use and program timing.
What to Watch Going Forward
The investment case centers on execution across the three oncology programs rather than quarterly financials. Management plans an end-of-Phase 2 meeting with the FDA in the first quarter of 2027 for the lead VMT-α-NET program in neuroendocrine tumors, which could clarify the route to a registration study. I’m watching closely for data updates from the VMT-α-NET cohorts, the VMT01 melanoma program, and the PSV359 solid-tumor effort. Recent catalysts include the October 2026 Fast Track Designation for PSV359 in FAP-positive solitary fibrous tumors and the September 2026 collaboration with Merck on a Keytruda combination study. Completion of the Chicago-area manufacturing facility in early 2027 will also be key for Lead-212 supply and scalability. Cost control remains relevant as R&D outlays grow in line with the stated runway into 2028.
Refining Research with AI Tools
When I want to cross-check biotech names against peers on technical patterns, fundamentals, and AI signals, Tickeron’s AI Screener helps narrow the field quickly. It lets users apply customizable filters for industry, market cap, volatility, and performance metrics to surface ideas more efficiently than manual searches. I find it useful for spotting potential comparables or confirming trends before digging deeper into individual filings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CATX sees MACD Histogram just turned negative
CATX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 43 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CATX as a result. In 80 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CATX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CATX entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where CATX advanced for three days, in 212 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
CATX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.296) is normal, around the industry mean (4.142). P/E Ratio (-0.632) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. CATX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CATX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of therapeutic radioactive isotopes
Industry MedicalNursingServices
Advertisement